Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: Histology, clinical chemistry and hematology

In Vivo

Volumn 20, Issue 3, 2006, Pages 325-332

  Larsen, Roy H ^a   Saxtorph, Henrik ^b   Skydsgaard, Mikala ^b   Borrebæk, Jørgen ^a   Jonasdottir, Thora J ^c   Bruland, Øyvind S ^d   Klastrup, Signe ^b   Harling, Robert ^b   Ramdahl, Thomas ^a  

^a Algeta ASA   (Norway)

^b LAB Research Denmark   (Denmark)

^c NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

223Ra; Alpha emitter; Bone seeker; Radiotoxicity

Indexed keywords

RADIOPHARMACEUTICAL AGENT; RADIUM 223; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERANCE; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; IN VIVO STUDY; LD 50; MALE; MESENTERY LYMPH NODE; MICROSCOPY; NONHUMAN; OSTEOBLAST; OSTEOCYTE; PERIPHERAL BLOOD STEM CELL; RADIATION DOSE; RADIATION HAZARD; RADIOACTIVITY; RAT;

EID: 33646894695     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Mulford DA, Scheinberg DA and Jurcic JG: The promise of targeted α-particle therapy. J Nucl Med 46: 199S-204S, 2005.
2. Imam S: Advancements in cancer therapy with alpha-emitters: a review. Int J Radiat Oncol Biol Phys 51: 271-278, 2001.
3. Ritter MA, Cleaver JA and Tobias CA: High-LET radiations induce a large proportion of non-rejoining DNA-breaks. Nature 266: 653-655, 1977.
4. Hieber L, Ponsel G, Roos H, Fenn S, Fromke E and Kellerer AM: Absence of dose-rate effect in the transformation of C3H 10T1/2 cells by alpha-particles. Int J Radiat Biol Stud Phys Chem Med 52: 859-869, 1987.
5. Behr TM, Memtsoudis S, Sharkey RM, Blumenthal RD, Dunn RM, Gratz S, Wieland E, Nebendahl K, Schmidberger H, Goldenberg DM and Becker W: Experimental studies on the role of antibody fragment in cancer radio-immunotherapy: influence of radiation dose and dose rate on toxicity and antitumor efficacy. Int J Cancer 77: 787-795, 1998.
6. Henriksen G, Bruland OS and Larsen RH: Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents. Anticancer Res 24(1): 101-105, 2004.
7. 224Ra for the treatment of ankylosing spondylitis: clinical experiences. Nucl Med Commun 23: 61-66, 2002.
8. Henriksen G, Breistøl K, Bruland ØS, Fodstad Ø and Larsen RH: Significant antitumor effect from bone-seeking, alpha particle-emitting radium-223 demonstrated in an experimental skeletal metastases model. Cancer Res 62: 3120-3125, 2002.
9. 89Sr in mice. J Nuclear Med 74: 252-259, 2003.
10. Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin J-E, Salberg G and Bruland ØS: First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11: 4451-4459, 2005.
11. 227Th source. Radiochim Acta 89: 661-666, 2001.
12. Borchardt PE, Yuan RR, Miederer M, McDevitt MR and Scheinberg D: Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 63: 5084-5090, 2003.